Cantor Fitzgerald Has Weak Forecast for TSHA FY2025 Earnings

Key Points

• Cantor Fitzgerald has downgraded its FY2025 earnings estimates for Taysha Gene Therapies, now predicting a loss of ($0.38) per share, compared to a prior estimate of ($0.33).
• The company reported a quarterly loss of ($0.09) per share, missing analysts' expectations, despite revenues of $1.99 million surpassing forecasts.
• Total institutional ownership in Taysha Gene Therapies is notably high at 77.70%, indicating strong investor interest in the stock.

Taysha Gene Therapies, Inc. (NASDAQ:TSHA - Free Report) - Equities researchers at Cantor Fitzgerald dropped their FY2025 earnings per share estimates for Taysha Gene Therapies in a research note issued on Wednesday, August 13th. Cantor Fitzgerald analyst K. Kluska now forecasts that the company will post earnings per share of ($0.38) for the year, down from their previous estimate of ($0.33). Cantor Fitzgerald currently has a "Overweight" rating and a $7.00 price target on the stock. The consensus estimate for Taysha Gene Therapies' current full-year earnings is ($0.35) per share. Cantor Fitzgerald also issued estimates for Taysha Gene Therapies' FY2026 earnings at ($0.52) EPS.

TSHA has been the subject of several other research reports. Chardan Capital raised their target price on Taysha Gene Therapies from $9.00 to $10.00 and gave the stock a "buy" rating in a research note on Tuesday, August 12th. JMP Securities raised their price target on Taysha Gene Therapies from $5.00 to $6.00 and gave the stock a "market outperform" rating in a research report on Thursday, May 29th. Bank of America began coverage on Taysha Gene Therapies in a research report on Friday, July 11th. They set a "buy" rating and a $8.00 price target for the company. Wells Fargo & Company raised their price target on Taysha Gene Therapies from $7.50 to $8.00 and gave the stock an "overweight" rating in a research report on Wednesday, August 13th. Finally, Citigroup restated an "outperform" rating on shares of Taysha Gene Therapies in a research report on Thursday, May 29th. Eight equities research analysts have rated the stock with a Buy rating, According to data from MarketBeat, the stock has an average rating of "Buy" and a consensus target price of $8.29.

Taysha Gene Therapies Trading Up 1.1%

TSHA stock traded up $0.03 during midday trading on Friday, hitting $2.87. 1,831,017 shares of the company's stock were exchanged, compared to its average volume of 2,882,316. The business has a 50-day simple moving average of $2.61 and a two-hundred day simple moving average of $2.14. The company has a current ratio of 12.48, a quick ratio of 12.48 and a debt-to-equity ratio of 0.17. The stock has a market capitalization of $616.08 million, a PE ratio of -8.44 and a beta of 0.98. Taysha Gene Therapies has a 1-year low of $1.05 and a 1-year high of $3.31.

Taysha Gene Therapies (NASDAQ:TSHA - Get Free Report) last posted its earnings results on Tuesday, August 12th. The company reported ($0.09) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.07) by ($0.02). The business had revenue of $1.99 million for the quarter, compared to analyst estimates of $1.61 million. Taysha Gene Therapies had a negative return on equity of 78.44% and a negative net margin of 1,144.97%.

Institutional Trading of Taysha Gene Therapies

A number of hedge funds and other institutional investors have recently bought and sold shares of TSHA. Jefferies Financial Group Inc. raised its stake in Taysha Gene Therapies by 4,105.3% in the second quarter. Jefferies Financial Group Inc. now owns 10,313,733 shares of the company's stock valued at $23,825,000 after buying an additional 10,068,479 shares in the last quarter. Octagon Capital Advisors LP raised its stake in Taysha Gene Therapies by 128.6% in the fourth quarter. Octagon Capital Advisors LP now owns 10,450,000 shares of the company's stock valued at $18,078,000 after buying an additional 5,877,778 shares in the last quarter. Adage Capital Partners GP L.L.C. acquired a new stake in shares of Taysha Gene Therapies during the fourth quarter worth about $8,650,000. MPM Bioimpact LLC acquired a new stake in shares of Taysha Gene Therapies during the second quarter worth about $6,823,000. Finally, Bank of America Corp DE increased its position in shares of Taysha Gene Therapies by 1,178.9% during the fourth quarter. Bank of America Corp DE now owns 1,710,303 shares of the company's stock worth $2,959,000 after purchasing an additional 1,576,568 shares in the last quarter. 77.70% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other Taysha Gene Therapies news, major shareholder Paul B. Manning purchased 750,000 shares of the business's stock in a transaction on Friday, May 30th. The shares were bought at an average cost of $2.75 per share, for a total transaction of $2,062,500.00. Following the completion of the purchase, the insider directly owned 2,841,704 shares in the company, valued at approximately $7,814,686. This represents a 35.86% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this link. 3.78% of the stock is currently owned by corporate insiders.

Taysha Gene Therapies Company Profile

Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis.